Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00050
|
|||||
| Drug Name |
Erythromycin
|
|||||
| Synonyms |
A/T/S; Abboticin; Abomacetin; Acneryne; Acnesol; Adecane-2,10-dione (non-preferred name); Ak-Mycin; Akne Cordes Losung; Akne-Mycin; Akne-mycin (TN); Aknederm Ery Gel; Aknemycin; Aknin; AustriaS; Benzamycin; Benzamycin Pak; C-Solve-2; Del-Mycin; Derimer; Deripil; Dotycin; Dumotrycin; E-Base; E-Base (base); E-Glades; E-Mycin; E-Mycin (base); E-Solve 2; E-mycin, Erycin, Robimysin; E0751; ERY; ERYC; ERYC (base); ERYTHROMYCIN STEARATE; Emgel; Emu-V; Emu-Ve; Emuvin; Emycin; Endoeritrin; Erecin; Erimycin-T; Erisone; Eritomicina; Eritrocina; Eritromicina; Eritromicina [INN-Spanish]; Ermycin; Eros; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-Tab (base); Ery-maxin; Eryacne; Eryacnen; Eryc (TN); Eryc 125; Eryc Sprinkles; Eryc-125; Eryc-250; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Erygel (TN); Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythra-Derm; Erythro; Erythro-Statin; Erythro-Teva; Erythroderm; Erythrogran; Erythroguent; Erythromast 36; Erythromid; Erythromycin & VRC3375; Erythromycin (JP15/USP/INN); Erythromycin A; Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Erythromycin Lactate; Erythromycin Ointment; Erythromycin [INN:BAN:JAN]; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Erythromycin, compd. with monododecyl sulfate, sodium salt; Erythromycine; Erythromycine [INN-French]; Erythromycinum; Erythromycinum [INN-Latin]; Erytop; Erytrociclin; Ilocaps; Ilosone (TN); Ilosone (estolate); Iloticina; Ilotycin; Ilotycin T.S; Ilotycin T.S.; Inderm; Inderm Gel; IndermRetcin; Kesso-Mycin; Latotryd; Lederpax; Mephamycin; Mercina; N-Methylerythromycin A; Oftalmolosa Cusi Eritromicina; Oftamolets; PCE Dispertab (base); Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pce (TN); Pharyngocin; Primacine; Propiocine; Proterytrin; R-P Mycin; Retcin; Robimycin; Romycin; Sans-acne; Sansac; Skid Gel E; Staticin; Staticin (TN); Stiemicyn; Stiemycin; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; T-Stat; T-stat (TN); Taimoxin-F; Theramycin Z; Tiloryth; Tiprocin; Torlamicina; Udima Ery Gel; Wemid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Syphilis [ICD11:1A60-1A6Z] | Approved | [1] | |||
| Chlamydia infections [ICD11:1C2Z] | Approved | [1] | ||||
| Pelvic inflammatory disease [ICD11:GA05] | Approved | [1] | ||||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C37H67NO13
|
|||||
| Canonical SMILES |
CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
|
|||||
| InChI |
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
|
|||||
| InChIKey |
ULGZDMOVFRHVEP-RWJQBGPGSA-N
|
|||||
| CAS Number |
CAS 114-07-8
|
|||||
| Pharmaceutical Properties | Molecular Weight | 733.9 | Topological Polar Surface Area | 194 | ||
| Heavy Atom Count | 51 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 14 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321305
,11335469
,11335572
,11335877
,11360708
,11360811
,11361116
,11362969
,11363553
,11365531
,11366115
,11368093
,11368677
,11374314
,11376255
,11376839
,11461680
,11461783
,11462088
,11484514
,11484962
,11488575
,11489079
,11492353
,11493929
,11494473
,12012581
,14720219
,14840178
,14864494
,25622201
,26611731
,26681121
,29280771
,46508487
,47365088
,47365089
,47662182
,47810649
,47885308
,47959639
,5020
,602912
,7847208
,7887354
,7979183
,8149330
,8159405
,823926
,855292
|
|||||
| ChEBI ID |
ChEBI:42355
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [4] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [5] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [6] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT2 | Transporter Info | Km =18.5 microM | Oocytes-OAT2 | [4] | |
| References | ||||||
| 1 | Erythromycin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. | |||||
| 3 | Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701. | |||||
| 4 | Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. | |||||
| 5 | Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. | |||||
| 6 | Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.